CareINSIGHTS.ai Introduced: 1st of Its Kind Clinical Intervention Program Powered by AI-based Predictive Modeling

CareINSIGHTS.ai was introduced today by Renalogic. CareINSIGHTS.ai is the first of its kind, clinical intervention program that is powered by AI-based predictive modeling, and is proven to help bend the catastrophic claims cost curve.

CareINSIGHTS.ai is the industry’s most advanced kidney care management program combining intelligence with tailored intervention to reduce the associated risk.

“We’re putting an end to surprise dialysis claims and changing the prognosis while reducing the hidden risk associated with CKD,” Mark Masson, President at Renalogic said. “The shift to identifying previously hidden risk results in a new, higher standard of chronic condition management. Today, we are identifying future CKD risk earlier than anyone else. CareINSIGHTS.ai can accurately predict when individuals will progress to higher acuity stages of chronic kidney disease and when they will progress to dialysis without proper intervention. This enables us to control future risk and provide the right care at the right time. We are helping to avoid growing claims costs associated with CKD and dialysis.”

CareINSIGHTS.ai arrives at a time when CKD continues to be the third-highest medical claims cost category. In 2020, estimated claims cost associated with CKD, which is often referred to as “the silent epidemic,” will total over $100 billion for commercial health plans. With new predictive modeling and AI, using hundreds of dimensions of data, CareINSIGHTS.ai can accurately predict each plan member’s propensity to advance to the next stage of CKD, including dialysis within the next 12 months. That’s every member, even those without a CKD diagnosis. This makes it possible to avoid the risk associated with CKD and dialysis, by delivering personalized intervention based on much more than the member’s CKD stage, including their trajectory and expected progression toward dialysis.

For more than a decade, Renalogic has been using data to mitigate CKD and dialysis risk. Now, CareINSIGHTS.ai is the next evolution of predictive modeling powered by AI. CareINSIGHTS.ai reports with 90% accuracy in identifying where and when CKD and dialysis claims will appear in the future. Over time, the predictive modeling will improve as it continues to think and learn as a “doctor.”

CareINSIGHTS.ai gives health plan administrators a look into future healthcare claims costs and utilization. “When we know what’s coming, we have time to avoid an emergent start to dialysis,” Masson said. Renalogic, a pioneer in dialysis cost containment, is again leading the industry by adopting a modern, AI-driven approach. “By taking the guesswork out of hidden risk, we’re giving health plan fiduciaries an extraordinary advantage compared to other dialysis cost containment options. CareINSIGHTS.ai layers claims cost containment and cost avoidance. What’s more, the proprietary predictive intelligence indicates future plan needs and could present additional savings for plans year over year.”

The Renalogic* Kidney Dialysis Avoidance Program (KDAP) successfully slows, stops and even reverses the progression of CKD. Nearly 80% of active KDAP members who have participated for six months or more have maintained or improved their CKD disease state. CareINSIGHTS.ai identifies additional risk earlier, identifies gaps in care and the leading indicator for each member’s trajectory toward dialysis. This makes personalized intervention as unique as each member’s fingerprint a reality for Renalogic clients.

Renalogic notes: For nearly two decades, we continue to be proud, forward-thinking leaders in a niche industry that is in crisis. We are an ambitious disruptor driving positive change to contain the catastrophic costs of dialysis. We are changing the way plan administrators think about dialysis. Chronic Kidney Disease (CKD) costs are an epidemic issue that will not resolve on its own. The logical approach is to get ahead of the curve. We are one company, one cause, leading the industry by empowering our clients to avoid dialysis altogether with solutions and technology for kidney disease management. No one does what we do. We exist to open minds, achieve sustainable results for our clients and be an advocate for kidney disease management, dialysis cost containment and prevention.

SourceRenalogic

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”